/
We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring ( CGM ) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our implantable CGM system ( Eversense ), including Eversense E3 and Eversense 365 CGM systems are designed to…
The business is unprofitable at the operating level (-193.83% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 56.9% YoY with margins expanding 139.2pp.
Negative free cash flow of -$60M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$41M
▲ +56.9% YoY
Net Income (TTM)
-$87M
▲ +12.1% YoY
Op. Margin
-212.95%
▲ +139.2pp YoY
ROIC
-62.95%
▲ +19.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$76M
▲ +3.9% YoY
Op. Cash Flow (TTM)
-$75M
▲ +2.2% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$64M
5Y CAGR: +48.1%
Continue Research